Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myeloma Immunoglobulin Idiotype Vaccine
- Development stage
- Phase 2
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular, Intradermal
01
Overview
Myeloma Immunoglobulin Idiotype Vaccine is a personalized cancer vaccine that targets the unique idiotype (Id) determinants on the monoclonal immunoglobulin (paraprotein) produced by malignant plasma cells in multiple myeloma. The idiotype, formed through gene rearrangement during B-cell maturation and somatic hypermutation, represents a tumor-specific antigen. The vaccine is designed to induce both humoral and cellular immune responses against these tumor-specific idiotypes, potentially eliminating residual disease after conventional treatments like autologous stem cell transplantation. Various delivery methods have been explored, including DNA-based vaccines, protein conjugates with keyhole limpet hemocyanin (KLH), and dendritic cell-based approaches.
- Other names
- Id vaccineId-KLH vaccineIdiotype vaccine
02
Targets
Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on Myeloma Immunoglobulin Idiotype Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myeloma Immunoglobulin Idiotype Vaccine.